Allplex™ SARS-CoV-2 Master Assay
Seegene IncFull Screening for SARS-CoV-2 and variants including five notable mutations in S gene
Seegene, Inc. is molecular diagnostic (MoDx) company that has been turning dreams of molecular diagnostic fields into reality through its pioneering R & D activities and novel technologies. Found in Seoul, Korea in 2000 and with having subsidiary in Rockville, MD, U.S.A., Seegene, Inc. has continued to develop innovative technology platforms, ACP™ (Annealing Control Primer), DPO™ (Dual Priming Oligonucleotide), and READ (Real Amplicon Detection) and stretch out globally to better respond to the needs of its valued customers. With these cutting-edge MoDx technologies applied to diagnostic kits and various practical approaches, Seegene has enhanced the sensitivity and specificity of PCR (polymerase chain reaction) up to unprecedented level. This advance enables Seegene, Inc. to provide multiplex PCR products by which multiple target genes of pathogens can be simultaneously detected, saving testing time and cost. Seegene, Inc. will continue to set new standards in MoDx and provide foundation for innovations to come.
Full Screening for SARS-CoV-2 and variants including five notable mutations in S gene
Detection of 4 target genes for SARS-CoV-2 using multiplex real-time PCR
High-throughput multiplex testing for identification of unknown pathogens
The 2X Multiplex Master Mix, optimized for the Multiplex PCR using Hot-start Taq., is a Pre-Mix product effective in amplifying a number of DNAs with just a one-time PCR. Key features include: 1. Optimization for Multiplex PCR 2. Contains non-specific outputs 3. Enhanced user convenience 4. Applicable in various tests